As the U.S. market experiences fluctuations with recent declines in major indices like the Dow Jones and S&P 500, investors are closely monitoring opportunities that might arise from these movements. In times like these, identifying stocks that appear undervalued relative to their fundamentals could offer potential for those looking to invest during a period of market recalibration.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Noble (NYSE:NE) $46.86 $93.04 49.6% Daqo New Energy (NYSE:DQ) $16.65 $32.90 49.4% Oddity Tech (NasdaqGM:ODD) $40.02 $78.89 49.3% Sachem Capital (NYSEAM:SACH) $2.87 $5.56 48.4% Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) $21.16 $41.49 49% Fluence Energy (NasdaqGS:FLNC) $16.49 $31.72 48% Sea (NYSE:SE) $68.76 $134.03 48.7% Vasta Platform (NasdaqGS:VSTA) $3.00 $5.80 48.3% TAL Education Group (NYSE:TAL) $10.05 $19.77 49.2% MediaAlpha (NYSE:MAX) $13.98 $27.76 49.6%

Click here to see the full list of 173 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Sotera Health

Overview: Sotera Health Company operates primarily in the sterilization, lab testing, and advisory services sectors both in the United States and internationally, with a market capitalization of approximately $3.78 billion.

Operations: The company's revenue is divided among three main segments: Sterigenics generates $673.63 million, Nelson Labs contributes $227.33 million, and Nordion adds $175.92 million.

Estimated Discount To Fair Value: 37.2%

Sotera Health is trading at US$13.24, significantly below its estimated fair value of US$21.08, highlighting a potential undervaluation based on discounted cash flows. Despite recent exclusion from multiple Russell indexes and a complex financial restructuring involving significant debt refinancing, the company shows promise with an expected earnings growth of 38.3% per year over the next three years. However, it's worth noting that interest payments are not well covered by earnings, posing a financial risk.

Upon reviewing our latest growth report, Sotera Health's projected financial performance appears quite optimistic. Dive into the specifics of Sotera Health here with our thorough financial health report. NasdaqGS:SHC Discounted Cash Flow as at Jul 2024

Atlantic Union Bankshares

Overview: Atlantic Union Bankshares Corporation serves as the holding company for Atlantic Union Bank, offering a range of financial products and services to both consumers and businesses in the United States, with a market capitalization of approximately $3.57 billion.



Operations: The company generates revenue through its Consumer Banking and Wholesale Banking segments, with earnings of $312.81 million and $292.95 million respectively.

Estimated Discount To Fair Value: 36.2%

Atlantic Union Bankshares is currently priced at US$39.16, which is 36.2% below its estimated fair value of US$61.4, suggesting potential undervaluation based on discounted cash flows. The company's earnings are expected to grow by 23.29% annually over the next three years, outpacing the US market forecast of 14.8%. Additionally, it offers a stable dividend yield of 3.27%. However, shareholders have experienced dilution in the past year, and revenue growth projections are not above the high-growth benchmark of 20% per year.

Our expertly prepared growth report on Atlantic Union Bankshares implies its future financial outlook may be stronger than recent results. Unlock comprehensive insights into our analysis of Atlantic Union Bankshares stock in this financial health report. NYSE:AUB Discounted Cash Flow as at Jul 2024

KBR

Overview: KBR, Inc. operates globally, offering scientific, technology, and engineering solutions to government and commercial clients with a market capitalization of approximately $9.03 billion.

Operations: The company's revenue is primarily generated from two segments: Government Solutions at $5.41 billion and Sustainable Technology Solutions at $1.66 billion.

Estimated Discount To Fair Value: 41.1%

KBR, priced at US$67.08, trades 41.1% below its fair value of US$113.86, indicating significant undervaluation based on discounted cash flow analysis. Expected to turn profitable within three years with an annual earnings growth of 40.97%, KBR's financial prospects are promising compared to the market average. Moreover, its revenue is projected to grow at 11.3% annually, surpassing the U.S market average of 8.6%. Recent contracts in renewable energy and defense sectors could further bolster its financial position and market standing.

Our comprehensive growth report raises the possibility that KBR is poised for substantial financial growth. Get an in-depth perspective on KBR's balance sheet by reading our health report here. NYSE:KBR Discounted Cash Flow as at Jul 2024

Summing It All Up

Discover the full array of 173 Undervalued US Stocks Based On Cash Flows right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:SHCNYSE:AUB and NYSE:KBR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]